An Oral Benzothiophene BDK Inhibitor Disclosed by Pfizer
BMS-986365, a heterobifunctional ligand-directed degrader of WT AR, exhibits low intrinsic agonism and direct antagonism via ligand-binding domain occupancy, leading to deep AR pathway inhibition and resistance combat. It shows a favorable preclinical profile and interim clinical data, differentiating from Arvinas' AR degraders.
Reference News
An Oral Benzothiophene BDK Inhibitor Disclosed by Pfizer
BMS-986365, a heterobifunctional ligand-directed degrader of WT AR, exhibits low intrinsic agonism and direct antagonism via ligand-binding domain occupancy, leading to deep AR pathway inhibition and resistance combat. It shows a favorable preclinical profile and interim clinical data, differentiating from Arvinas' AR degraders.